Search Results

We thank Jaydira Del Rivero, MD, for reviewing this blog post. In March 2025, the U.S. FDA approved a new treatment option for neuroendocrine tumors: cabozantinib. (Cabometyx® is the brand name of this medication, manufactured by Exelixis.) Although this pill has long been used to treat other cancers, it is now approved for patients 12 years and older with previously treated, advanced neuroendocrine tumors. 👉 For background on the CABINET trial and what the trial data showed, read our March 26, 2025 blogpost: Positive Results of the CABINET Trial Show Cabozantinib as a New, Effective Treatment in Advanced Neuroendocrine Tumors  and watch our Nov 2025 Interview with Dr. Aman Chauhan Update on Cabozantinib . Cabozantinib is an oral, non-chemotherapy pill from the category of medications called a VEGF tyrosine kinase inhibitor (or TKI) . It's a targeted therapy that works to inhibit the growth of blood vessels in the tumors and also can work to slow growth.  As more patients begin taking cabozantinib, it has become one of the most frequently discussed topics in our weekly support groups. Many people want to know what to expect, how to take the medication correctly, how it may affect daily life, and what practical steps can help them feel more prepared. Below are tips and tricks gathered from firsthand patient and caregiver experience, including NET caregiver Lisa Yen’s “show and tell,” which offers practical tools she and her husband found helpful when preparing for Cabozantinib. Important: Always consult your healthcare team with any questions or concerns about your care. This information is provided solely for educational purposes to support and inform patients and caregivers. It is not intended to substitute for professional medical advice, clinical judgment, diagnosis, or treatment, nor should it replace direct discussions with your healthcare providers. Download the transcript of this video >>> Key Resources and Helpful Items 1. Order the free Cabometyx® Patient Care Kit and join the Be Connected  support program The Cabometyx Patient Care Kit is available directly from the manufacturer, Exelixis and includes: Samples to help manage common side effects Educational materials on cabozantinib A treatment journal to track symptoms, blood pressure readings, and communication with your care team A patient handbook with tips and guidance Many patients find this kit reassuring and helpful to have on hand. 2. Listen to Podcast Episode 50: Spotlight on Pharmacists Pharmacists, especially oncology pharmacists, play a key role in helping patients navigate targeted oral therapies. This episode discusses: How to take cabozantinib safely What to avoid Common drug interactions Ways to manage side effects How pharmacists can support you throughout treatment Udderly Smooth® cream Cabozantinib can cause hand foot syndrome, a side effect that may lead to redness, sensitivity, or discomfort in the hands and feet. Patients often find that the over-the-counter Udderly Smooth cream: Helps moisturize dry or irritated skin Is non-greasy Works well when applied at bedtime Blood Pressure Cuff Cabozantinib can increase blood pressure, so monitoring at home is essential.  Tips: Check your blood pressure at the same time each day, preferably in the morning Record each reading so your care team can identify trends Know the parameters for when to call your doctor.  Your doctor may prescribe medications to manage your blood pressure. Ask your doctor who you should be reporting your blood pressure readings to and who will be the one to prescribe and manage high blood pressure. 5. Helpful Items for Nausea or Altered Taste Some people taking cabozantinib experience nausea or altered taste. The following tips and tools may help manage these symptoms: Lemon or lime  Some people find adding a few drops of lemon or lime to their water helps with altered taste or nausea.  Herbal inhaler   Some patients find that inhaling soothing herbal scents can help ease nausea. Lozenges Products such as Organic Morning Ease by Traditional Medicinals  or Tummy Drops peppermint lozenges  may help soothe nausea. Nonmetal utensils Using bamboo or other non-metal utensils may help reduce metallic taste during meals, if this is one of your symptoms. Biotène® oral rinse Some patients experience dry mouth, mouth sores, or changes in taste. An alcohol-free over-the-counter rinse like Biotène can soothe mouth dryness, reduce discomfort, and make eating easier when used before meals. If nausea persists, ask your doctor about prescription anti-nausea medications. Your care team can help determine what is appropriate for you. The following guidance is adapted from patient education materials provided by the manufacturer of cabozantinib (Exelixis, maker of the FDA-approved drug Cabometyx®). For more information, visit:   https://www.cabometyx.com/resources Always discuss any questions or concerns with your healthcare team before making changes or trying new strategies. How to Take Cabozantinib Swallow tablets whole. Do not crush, chew, or dissolve them Take on an empty stomach: one hour before eating or two hours after eating Take it at the same time each day. Any time of day is fine as long as it is consistent If you miss a dose and more than 12 hours have passed, skip it and take the next scheduled dose Food and Drug Interactions While taking cabozantinib, do not eat or drink grapefruit, grapefruit juice, or grapefruit-containing products because they can affect how the medication is absorbed. Inform your health care provider of all medications you take, including prescription medications, over-the-counter products, vitamins, and herbal supplements. This helps your care team identify any possible interactions and keep you safe during treatment. Monitoring Symptoms Track symptoms such as: Mouth sores Changes in taste Dry mouth Hoarseness or voice changes Skin and hair changes, such as changes in color, dry skin, rash Fatigue Digestive issues such as nausea or diarrhea Daily tracking helps your provider decide whether dose adjustments, side effect management strategies, or treatment breaks are needed. Communication Is Key Frequent communication with your healthcare team, supported by your journal or tracking system, helps ensure the treatment is safe, tolerable, and effective. Final Thoughts Starting a new medication can bring uncertainty, especially when it affects daily routines. These tips and tools have helped many people feel more prepared and empowered as they begin Cabozantinib. For more information and resources, explore our video library  and podcasts . You are not alone. We are here to support you.

Dear Neuroendocrine Cancer Community, Dr. Richard R.P. Warner For six decades years, the Carcinoid Cancer Foundation (CCF) has been a pillar of education, advocacy, and support for the neuroendocrine tumor (NET) community. Founded by the late Dr. Richard R.P. Warner , CCF helped shape the modern landscape of NET patient education and touched countless lives. The Neuroendocrine Cancer Foundation (NCF) now enters a new chapter as we carry forward this legacy. We have been entrusted with continuing programs and resources that have supported patients and families for decades. Serving as the successor to this 60-year foundation is both an honor and a responsibility we do not take lightly. We are grateful for the trust placed in NCF to steward this work and build upon Dr. Warner’s vision. That trust reflects a shared commitment to ensuring people affected by neuroendocrine cancer have continued access to reliable information, compassionate support, and meaningful connection. Our mission remains clear: no one facing neuroendocrine cancer should feel alone. We will continue providing trusted education, patient support, and community engagement while investing in initiatives that advance care, awareness, and quality of life. How We Will Continue This Important Work Over the past two years, NCF has worked alongside CCF to ensure continuity of support through the patient support line, the Luncheon with the Experts (LWTE)  webinar series, Stories of Hope , and other educational initiatives. These programs will continue under NCF. Neuroendocrine Cancer Provider Directory Building on CCF’s “Find a Doctor” database, NCF is partnering with the Neuroendocrine Tumor Research Foundation (NETRF) to combine two specialist databases into a single, comprehensive Neuroendocrine Cancer Provider Directory. This unified, up-to-date resource will help patients and caregivers connect with experienced specialists and is planned for launch later this year. LWTE Webinars, Stories of Hope, and Support Line These cornerstone programs will continue under the NCF umbrella. We invite you to stay connected and engaged with our community: Facebook Instagram YouTube X (formerly Twitter) LinkedIn We extend our sincere gratitude to CCF for its decades of service and to CCF's CEO Keith Warner, and COO Grace Goldstein (retired in 2022), for ensuring Dr. Richard Warner’s legacy continues. We also thank you—the neuroendocrine cancer community—for your continued trust as we carry this work forward. With respect and gratitude, NCF Team Other Resources Learn more about the Neuroendocrine Cancer Foundation Sign up for our upcoming patient programs

2025 was a year of meaningful progress in neuroendocrine cancer. New treatments, new clinical trial data, and expanded research efforts continue to improve care for people living with diverse neuroendocrine cancers including neuroendocrine tumor (NET), neuroendocrine carcinoma (NEC), and pheochromocytoma and paraganglioma (PPGL). Below is an overview of some of the most important developments of the year. Year-in-Review: NET and NEC Updates Download the transcript of this video >>> Dr. Udhay Grewal summarizes major advances from conferences and clinical trials across the NET and NEC landscape. Key Advances Continued progress in alpha PRRT, including completion of the ACTION 1 Actinium 225 trial. FDA approval of belzutifan for pheochromocytoma and paraganglioma. Promising results from DLL3 targeted therapies for high grade NEC. Ongoing development of tri-specific antibodies and DLL3 radioligand therapies. New Developments in Neuroendocrine Tumors (NETs) Download the transcript of this video >>> 2025 brought several promising updates for patients with well-differentiated NETs. Dr. Aman Chauhan highlights the following: Key Advances Paltusotine : A once-daily pill being studied for carcinoid syndrome. Alpha PRRT : Early activity seen with Lead-212 and Actinium-225 therapies. Combination PRRT : Triapine plus Lutetium-177 shows encouraging safety and early effectiveness. New targeted therapy : Zanzalintinib is being evaluated as a next-generation VEGF inhibitor. New Developments in Neuroendocrine Carcinoma (NEC) Download the transcript of this video >>> High-grade NEC has historically had fewer treatment options, but 2025 delivered real momentum. Dr. Aman Chauhan discusses the following: Key Advances DLL3 T-cell engagers:  Including tarlatamab and the investigational drug obrixtamig. Oncolytic virus therapy:  Seneca Valley Virus combined with immunotherapy is being studied. DLL3 radiopharmaceuticals:  New therapies under development that may bring theranostics to NEC. COMPETE Trial Results Presented at ENETS 2025 Download the transcript of this video >>> At the ENETS Congress in March 2025, NANETS President Emeritus Dr. Halfdanarson explained key results from the COMPETE phase 3 trial comparing PRRT Lu 177 DOTATOC with everolimus. He also discusses what it means for patients. Key Takeaways PRRT was more effective than everolimus in delaying tumor growth. Side effects were expected and consistent with previously known PRRT safety. Quality-of-life data are pending, but past studies suggest favorable outcomes. Everolimus remains an important option. The goal is ensuring patients receive all effective treatments over time. 2025 Highlights and Future Directions from NANETS President Dr. Jennifer Chan Download the transcript of this video >>> At the September 2025 INCA Summit in Sofia, Bulgaria, NANETS President, Dr. Jennifer Chan reflected on the progress of the past year and shared what she is most excited about for the future: Key Highlights Cabozantinib approval  Dr. Chan discussed the impact of cabozantinib’s approval for both pancreatic and extra pancreatic NETs and described how this expands treatment access for patients worldwide. Belzutifan approval for PPGL   She highlighted the approval of belzutifan as a major step forward for people with pheochromocytoma and paraganglioma. Broader research momentum  Growth in the number of physicians, scientists, and centers engaged in NET and NEC research has transformed the field. Upcoming trial readouts  Dr. Chan emphasized the importance of recently completed studies, including COMPETE, and expressed enthusiasm for ongoing alpha PRRT studies and other next generation therapies. Cabozantinib Results Highlighted at ESMO 2025 Download the transcript of this video >>> In October 2025, new subgroup data on lung and thymic NET from the CABINET study were presented at ESMO. This followed the FDA approval of cabozantinib in March 2025. Dr. Aman Chauhan explains what this means for patients: Key Takeaways Strong benefit seen in lung NETs, including typical and atypical carcinoids. Activity observed in higher grade well-differentiated NETs. An important treatment option for people who are not eligible for PRRT or somatostatin analogs. NANETS 2025: Top 12 Highlights Our Neuroendocrine Cancer Foundation podcast with Dr. Will Pegna offers an easy-to-understand review of the most important updates from the 2025 NANETS symposium. Visit the podcast page for more information and resources >>> Bridging Inequities in Neuroendocrine Cancer Care Download the transcript of this video >>> A meaningful highlight of 2025 was the growing recognition of inequities in neuroendocrine cancer care and the expanding commitment across the field to address them. Dr. Grewal, who was honored with the inaugural NANETS Diversity, Equity, and Inclusion Award, shared why this work is essential and how patients and advocates can help drive meaningful change. Key Insights Many patients seen in everyday practice do not resemble those typically enrolled in clinical trials. Racial and ethnic minority groups, as well as rural patients, often face major barriers to receiving standard of care treatment and participating in research. Recent studies highlight disparities in clinical trial enrollment and end-of-life care, including lower access to palliative care among Black patients. Researchers are using NETPRO and other datasets to better understand gaps and inform future solutions. Why This Matters Dr. Udhay Grewal emphasized that progress is meaningful only when it reaches everyone who needs it. As new therapies emerge, ensuring equitable access is essential. How Patients and Caregivers Can Help Get involved in advocacy and awareness efforts. Share your experiences to help shape research and improve care. Partner with organizations like NCF, NANETS, and ASCO to support equity-focused initiatives. Looking Ahead to 2026 We look forward to the launch of new clinical trials and the results of several important ongoing studies, including those evaluating combination PRRT strategies, multiple alpha PRRT agents, DLL3-targeted therapies, and new oral treatment options. Progress is accelerating, and as research expands, so do the treatment options and sources of hope available to patients. As our speakers emphasized, meaningful advances are happening. There is real reason to be hopeful. And together, we can continue to move the field forward.  THANKS TO OUR SPONSORS

The Neuroendocrine Cancer Foundation Podcast (previously known as the LACNETS Podcast) is a monthly series where we interview neuroendocrine tumor (NET) experts on various NET topics. Each expert will answer the top 10 FAQs in their area of expertise. Whether a listener is newly diagnosed, a longtime NET survivor, or a family member or loved one, the Neuroendocrine Cancer Foundation Podcast serves as a tool to help anyone better understand NET. The Neuroendocrine Cancer Foundation Podcast is also available on Apple Music, Spotify, Google Podcasts, and Amazon Music. Be sure to subscribe to our podcast to receive notifications when new episodes are released! 2026 2025 2024 2023 2022 2021 2026 2026 LISTEN 2025 2025 LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN 2024 2024 LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN 2023 2023 LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN 2022 2022 LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN 2021 2021 LISTEN LISTEN LISTEN LISTEN LISTEN

<< Go back to the Podcast page EPISODE 26: WHAT TO KNOW ABOUT LUNG NETS Download the transcript here: LACNETS Podcast Episode 26_Lung NETs .pdf Download PDF • 208KB ABOUT THIS EPISODE What are lung NETs? What is DIPNECH? How is lung NET similar or different from lung cancer? Dr. Vineeth Sukrithan from Ohio State University Comprehensive Cancer Center gives a comprehensive overview of lung NET and DIPNECH, including the work-up and treatment options. He also discusses open clinical trials and exciting advances in lung NET research on the horizon. MEET DR. VINEETH K. SUKRITHAN Dr. Vineeth Sukrithan is a medical oncologist who specializes in the study and treatment of neuroendocrine cancer, thyroid cancer and adrenocortical cancer. He utilizes traditional chemotherapy, molecularly targeted oral medications, novel immunotherapy and peptide-receptor radiotherapies in the treatment of these unique cancers. As a comprehensive cancer center, the OSUCCC – James has unrivaled experience and expertise in the treatment of neuroendocrine, thyroid and adrenal tumors. Their world-renowned faculty are leaders in the study and treatments of these rare cancers, and as such, they are able to provide their patients with options beyond standard therapies that may not be available anywhere else. The strong focus on translational research at The James means that the treatment breakthroughs of tomorrow are being discovered in their laboratories today. Dr. Sukrithan is part of a tight-knit team of surgical oncologists, radiation oncologists and interventional radiologists who work together to provide cutting-edge care for our patients with neuroendocrine tumors. In addition to his clinical work, Dr. Sukrithan is a member of the Translational Therapeutics Program at the OSUCCC – James and the co-director of the Adrenal Tumor Clinic. He was recently selected to lead an externally funded effort through the International Thyroid Oncology Group to operationalize a multi-institutional registry database for patients with medullary thyroid cancer. Dr. Sukrithan also serves as an assistant professor in the Division of Medical Oncology at The Ohio State University and has completed postdoctoral fellowships in clinical research at Johns Hopkins University. His research has been published in numerous peer-reviewed journals, including Cancer Research, American Journal of Clinical Oncology and Clinical Lung Cancer. As every individual’s cancer is molecularly unique in countless ways, Dr. Sukrithan believes in tailoring therapies to the individual with the precision made available through cutting-edge scientific research. He feels it is a privilege to make a difference in the lives of patients as we work together to achieve a cancer-free world. TOP 10 QUESTIONS What are lung NETs? Where are they located? How are lung NETs found? What are the symptoms of a lung NET? How is lung NETs different (or similar) to what is commonly referred to as “lung cancer”? How is it different or similar to DIPNECH? Do all lung NET patients have DIPNECH and do all DIPNECH patients have lung NET? How is lung NET similar or different from other types of NETs? What makes it unique? What types of labs, scans, or testing is done to determine if someone has a lung NET and DIPNECH? What is the best type of scan for lung NETs? How do you decide if the lung NET can be surgically removed? What type of surgeon would make that determination and when in their patient journey might they see a surgeon? How are lung NETs treated medically (or nonsurgically)? How are the treatments different from other NETs? How are treatments sequenced? How are lung NETs monitored? What types of blood work, tests and scans should be done and how often should they be done? What advances in the field or clinical trials should we be aware of? What new advances or treatments in the pipeline for lung NETs are you most excited about? RESOURCES Lung NET Clinical Trials mentioned in this episode: PRRT TRIAL for lung NET: phase 2 trial studying the effect of lutetium Lu 177 dotatate (PRRT) compared to the usual treatment (everolimus) in treating patients with somatostatin receptor positive ADVANCED bronchial Neuroendocrine Tumors CABINET: Cabozantinib in Advanced pNET and Carcinoid Tumors A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms in Clinical Cancer Research Lung NET Resources: LACNETS Lung NET Resources Lung NET Clinical Trials in the LACNETS Clinical Trials Guide WATCH: https://www.youtube.com/watch?v=21HKeWI0d3g NET Patient Dorinda shares her NET Journey https://www.youtube.com/watch?v=Mww9tKWZxfQ "Focus on Lung Carcinoid Tumors" with Dr. Robert Ramirez https://www.youtube.com/watch?v=STkKpCVNtXo "Update on Lung NETs" with Dr. Sukhmani K. Padda DISCLAIMER LACNETS Podcasts are created for educational purposes only and do not substitute for medical advice. The views shared in this Podcast are the personal opinions of the experts and do not necessarily reflect the views of LACNETS. Please contact your medical team with questions or concerns about your individual care or treatment. THANK YOU TO OUR SPONSORS

See videos of recent educational events on various topics on neuroendocrine cancer Recent Events "Just Diagnosed With Neuroendocrine Cancer? What to Know and Understand" April 23, 2026 Being newly diagnosed with neuroendocrine cancer (NETs) can feel overwhelming. Many patients find themselves asking, “What exactly is neuroendocrine cancer, and how is it different from other cancers?” This webinar is designed to bring clarity, reassurance, and guidance during one of the most confusing stages of the NET journey. Watch "Luncheon With The Experts" with Dr. Boris G. Naraev Mar 26, 2026 “Luncheon With The Experts” is a recurring educational outreach series (previously hosted by the Carcinoid Cancer Foundation) aimed at patients, caregivers, and the broader neuroendocrine cancer community. The sessions are hosted by Rain Bennett. Watch "Novel Targeted Therapies in Neuroendocrine Cancers" Mar 9, 2026 Join us for a discussion of targeted therapies in neuroendocrine cancer, one of the fastest-growing areas of NET treatment. Unlike traditional chemotherapy, targeted therapies focus on specific pathways or features of cancer cells. Understanding how these treatments work can help patients feel more confident and informed when discussing options with their care team. Watch "The Latest in Neuroendocrine Cancer Clinical Trials" Feb 20, 2026 Join us for an overview of the latest clinical trials in neuroendocrine cancer with Dr. Heloisa Soares, a medical oncologist and physician-scientist at the Huntsman Cancer Institute (HCI) in Salt Lake City. Dr. Soares will walk through key neuroendocrine cancer clinical trials including what they are studying, what makes them exciting, and how they may shape future treatment options. She will also explain why clinical trials matter, how they benefit patients, and what to consider when exploring whether a trial might be right for you. Whether you’re a patient, caregiver, or simply trying to stay informed, this webinar will provide clear, practical insights to help you better understand emerging research and what it means for the neuroendocrine cancer community. Watch The Latest in the Management of Functional Neuroendocrine Cancers Jan 21, 2026 Join us for an easy-to-understand overview of functional neuroendocrine tumors (NETs) with Dr. Jaydira Del Rivero, a medical oncologist and endocrinologist at the National Cancer Institute. Functional NETs can cause the body to produce too many hormones, leading to challenging symptoms such as low blood sugar (often seen in insulinoma), high blood sugar (glucagonoma), carcinoid syndrome (excess serotonin), and other hormone-related issues and symptoms. Dr. Del Rivero will explain what these syndromes are, how they’re diagnosed, and the latest updates in treatment. She will also discuss conditions that can occur because of NETs or their treatments such as adrenal insufficiency. She will help patients understand why symptoms like hypoglycemia are more common in some NET types. Whether you’re a patient, caregiver, or simply want to better understand functional NETs, this webinar will offer practical, up-to-date information to help you feel more informed and empowered. Watch The Latest on Immunotherapy for Neuroendocrine Cancer Dec 11, 2025 Immunotherapy is an exciting and rapidly advancing area in the treatment of neuroendocrine cancer. Join Dr. Aman Chauhan, medical oncologist at the University of Miami Sylvester Cancer Center, as he discusses the latest developments in immunotherapy for NETs. This webinar will cover current standard-of-care treatments as well as cutting-edge clinical trials involving DLL3-targeted therapies, oncolytic viruses, CAR T-cell therapy, and combination approaches. Whether you’re newly diagnosed or exploring new treatment options, this session will help you better understand the evolving landscape of immunotherapy in neuroendocrine cancer. Event Page NCF Regional NET Patient Educational Event Nov 9, 2025 Join the Neuroendocrine Cancer Foundation and the Sylvester Comprehensive Cancer Center, part of UHealth – University of Miami Health System, in Miami, Florida, on Sunday, November 9th, from 8:30 am - 4:30 pm. More Info Coping With Neuroendocrine Cancer: Managing Distress, Worry & Grief Oct 28, 2025 A neuroendocrine cancer diagnosis can bring emotional, mental, and psychological challenges that are just as difficult as the physical ones. Join licensed clinical psychologist Dr. Karen Kersting from the Medical College of Wisconsin for a supportive discussion on Coping with Neuroendocrine Cancer: Managing Distress, Worry & Grief. She will offer insights and practical strategies to help patients and caregivers navigate the full emotional and psychological impact of living with NETs. Event Page Understanding Alpha & the Evolving PRRT Landscape Sep 22, 2025 The field of PRRT (Peptide Receptor Radionuclide Therapy) is evolving rapidly, and patients are hearing more about new developments like alpha therapies, the recent NETTER-2 and COMPETE trial results, and other advances. Join medical oncologist Dr. Udhayvir Singh Grewal from the Winship Cancer Institute of Emory University as he breaks down what these changes mean for people living with neuroendocrine cancer. This webinar will help patients and caregivers make sense of emerging research and therapies—and what they may mean for the future of NET treatment. Event Page Nutrition & Diet Considerations for NETs Aug 26, 2025 Nutrition can play a key role in living well with neuroendocrine cancer (neuroendocrine tumors or NETs). Join NET dietitian Meghan Laszlo for an informative session on nutrition and diet considerations for people living with neuroendocrine cancer. Event Page Living with NET: The Patient Perspective July 10, 2025 Join us for an open and honest conversation with four individuals living with neuroendocrine cancer as they share the realities of navigating life with an uncommon cancer. Event Page 2025 NCF Neuroendocrine Cancer Patient Conference June 14, 2025 Our 2025 NCF Neuroendocrine Tumor Patient Conference is designed for neuroendocrine cancer (NET or neuroendocrine tumor) patients and caregivers to deepen your understanding of NETs. Event Page NCF Regional NET Patient Educational Event May 17, 2025 The Neuroendocrine Cancer Foundation is hosting an in-person Neuroendocrine Cancer Educational Event for patients and caregivers in Santa Monica, California on Saturday, May 17th, from 3:45 -7:30 PM. Read the Event Blogpost "Evolving Management of Carcinoid Heart Disease: What We Know & What's New" April 29, 2025 Learn from Cardiologist and Congenital Heart Disease Specialist, Dr. Prashanth Venkatesh from Cedars-Sinai Smidt Heart Institute in a virtual educational event on carcinoid heart disease. Dr. Venkatesh demystifies the topic and shares the latest developments in its diagnosis and treatment, including a novel minimally invasive approach to replace heart valves damaged by carcinoid heart disease. Event Page "Understanding Treatments for Neuroendocrine Tumors and Rationale for Sequencing of Therapy" April 1, 2025 Learn from internationally-renowned neuroendocrine cancer expert Dr. Edward Wolin in a discussion on the latest in neuroendocrine tumor treatments and understanding how to sequence them. Dr. Wolin has pioneered many of the NET treatments including somatostatin analogues (SSAs, sandostatin and octreotide), mTOR inhibitors (i.e. everolimus), anti-angiogenic drugs (i.e. cabozantinib), and peptide receptor radiotherapy (PRRT, i.e. Lutathera). Listen to this insightful presentation and live question and answer session. Event Page NCF Regional NET Patient Educational Event March 29, 2025 The Neuroendocrine Cancer Foundation is hosting an in-person NET Educational Event for patients and caregivers in Tucson, Arizona on Saturday, March 29th, from 1:30-6:00 PM. Read the Event Blogpost "PRRT Nurse's Perspective: What to Expect with PRRT" March 7, 2025 Learn about PRRT from UCLA's Lead PRRT Nurse Linda Gardner. She addresses common questions about what to expect before, during, and after the treatment, as well as concerns about radiation safety. Event Page "Deciphering Genetics & Genomics in Neuroendocrine Cancers" with Dr. Kimberly Perez Feb 7, 2025 Learn the latest in genetics and genomics for neuroendocrine cancers from medical oncologist Dr. Kimberly Perez from Dana Farber Cancer Institute (DFCI) in Boston, Massachusetts. Dr. Perez has expertise in hereditary cancer syndromes and deciphers the topics of genetics and genomics. Event Page "Understanding GI NETs Found on Endoscopy: Gastric, Duodenal, Colon & Rectal" with Dr. David Metz Jan 28, 2025 Learn from renowned Neuroendocrinologist Dr. David Metz, who discusses neuroendocrine tumors (NETs) found on endoscopy, including gastric, duodenal, colon and rectal NETs. Dr. Metz discusses which NETs can be found on endoscopies and how they are managed and treated. Event Page Comprehensive Guide to Lung Neuroendocrine Cancers: From Typical Carcinoids to Small Cell Lung Cancer (SCLC) Tuesday, Dec 10, 2024 Learn all about lung neuroendocrine cancers from neuroendocrine cancer expert Dr. Aman Chauhan, leader of the Neuroendocrine Tumor Program and Co-Director of the Theragnostic Program at the Sylvester Comprehensive Cancer Center, University of Miami. Dr. Chauhan will give a comprehensive guide to lung neuroendocrine cancers ranging from typical carcinoids to small cell lung cancer. Event Page Palliative Care for Neuroendocrine Cancer Thursday, Nov 14, 2024 Learn about Palliative Care: what it is, what it is not, and how it may help those affected by neuroendocrine cancer. Dr. Chandana Banerjee, palliative care and hospice specialist from the City of Hope Cancer Center in Los Angeles, demystifies these topics. Event Page 2024 NET Cancer Day Symposium Saturday, November 9, 2024 Celebrate with us at the 2024 LACNETS NET Cancer Day Symposium in Santa Monica, California on Saturday, November 9th from 8:30 am - 4:30 pm. Event Page Evolving Management of NET Liver Metastases Friday, October 18, 2024 Hear the renowned liver and pancreas surgeon, Dr. Gagandeep “Gaugs” Singh, discuss the evolving algorithms in managing NET liver metastases. Dr. Singh, Chief of Surgical Oncology at City of Hope® Cancer Center in Phoenix, asks the question of whether it is prudent to be aggressive surgically or if it is all about timing and strategy. Regional NET Patient Education Conference Saturday, September 21, 2024 LACNETS is hosting an in-person NET Educational Event for patients and caregivers in Minneapolis, Minnesota, on Saturday, September 21st, from 1:30-5:00 PM. This event was not live-streamed or recorded. Meet the Expert: Dr. Eric Liu Saturday, August 17, 2024 Join LACNETS in Denver, Colorado for an in-person event. Meet NET expert Dr. Eric Liu who will give a broad survey of NET from diagnosis to treatment and philosophy. Engage in an interactive question and answer session with Dr. Liu. It’s a wonderful opportunity to learn, advocate and connect in-person with a NET expert and fellow NET patients and caregivers. 2024 LACNETS Neuroendocrine Tumor Patient Conference Saturday, June 15, 2024 Join us for the biggest LACNETS event of the year featuring more than ten NET experts. This year's theme is Deepening Your Understanding of NETs. Event Page High Grade Neuroendocrine Neoplasms & Small Cell Lung Cancer Tuesday, May 7, 2024 Learn about the latest in high grade neuroendocrine neoplasms and small cell lung cancer with medical oncologist Dr. Aman Chauhan, Leader of the Neuroendocrine Tumor Program and Co-Director of the Theragnostic Program at the Sylvester Comprehensive Cancer Center, University of Miami. 2024 Updates: Neuroendocrine Cancer Clinical Trials Thursday, April 25, 2024 Learn about the latest in clinical trials for neuroendocrine cancer with NET expert Dr. Heloisa Soares, a medical oncologist at the Huntsman Cancer Institute (HCI) at the University of Utah. TKIs: Tyrosine Kinase Inhibitors & Neuroendocrine Tumors Friday, Mar 29, 2024 Learn about Tyrosine Kinase Inhibitors (TKIs), what they are and how they work with NET expert Dr. Jennifer Chan. Dr. Chan is the Vice President of the North American Neuroendocrine Tumor Society (NANETS) and the principal investigator of the CABINET trial. Hear the positive findings from that TKI study using Cabozantinib. She discusses the latest in TKI treatments and how they may be a possible treatment option for many NET patients. LACNETS Educational Event Feb 14, 2024 Join us to learn about Carcinoid Heart Disease from Cardiologist Dr. S. Allen Luis at the Mayo Clinic in Rochester, MN. He will describe the cause and symptoms of carcinoid heart disease and discuss diagnosis, treatment and surveillance. LACNETS Educational Event "PRRT: What We Know, Special Considerations & Clinical Trials" with Dr. Jonathan Strosberg January 11, 2024 Join us on Thursday, January 11th at 9:30 AM Pacific to learn the latest on PRRT with NET expert Dr. Jonathan Strosberg. Dr. Strosberg was the principal investigator of the NETTER-1 study which led to the FDA approval of Lutathera and has authored numerous articles on PRRT. He will discuss the latest in PRRT, including special considerations and current clinical trials. LACNETS Educational Event "Minimally Invasive Treatments for Neuroendocrine Liver Metastases" with Dr. Yilun Koethe Dec 9, 2023 Join us to learn more about minimally invasive liver-directed therapies targeting liver metastases with interventional radiologist Dr. Koethe. She discusses ablations including the recently approved histotripsy and embolizations including bland, chemo, and radioembolization. LACNETS Educational Event "Symptoms Management" with Dr. David Metz Oct 10, 2023 Join LACNETS to hear Neuroendocrinologist Dr. David Metz from University of Pennsylvania discuss symptom management. The presentation will cover carcinoid syndrome, pancreatic enzymes, bile acid secretion, and short bowel syndrome. He will explain current treatments, supplements, and diets that might be helpful to control NET-related symptoms. LACNETS Educational Event "Navigating Clinical Trials: Expectations Vs. Realities" with Taymeyah Al-Toubah, MPH Aug 19, 2023 Hear Taymeyah Al-Toubah, MPH, Senior Research Project Manager at the Neuroendocrine Tumor Program of Moffitt Cancer Center. LACNETS Educational Event "Surgery: The What, Where & When" with Dr. Eric Liu July 7, 2023 Hear NET expert Dr. Eric Liu of Rocky Mountain Cancer Centers discuss “Surgery: The What, Where & When.” 2023 LACNETS Annual NET Patient Conference June 17, 2023 Watch our biggest event of the year with 12 NET experts from North America. WATCH NOW LACNETS E ducational Event Topic: High Grade Neuroendocrine Neoplasms (NEN) May 4, 2023 Join LACNETS on May 4th for an educational event dedicated to high grade neuroendocrine neoplasms (NENs). Medical oncologist Dr. Jason Starr from Mayo Clinic in Jacksonville, Florida, will discuss the management and treatment of high grade NENs, including the latest updates and clinical trials. LACNETS Educational Event: "What's New in PRRT" April 14, 2023 Join Dr. Amir Iravani, a Nuclear Medicine Physician and Theranostics Director at Fred Hutchinson Cancer Center, to hear the latest on Peptide Receptor Radionuclide Therapy (PRRT). Better understand the difference between beta and alpha PRRT, current trials and updates on PRRT for Lung NET, adolescents and dosimetry. LACNETS Educational Event: "Update on NET Clinical Trials" March 10 , 2023 Join Dr. Heloisa Soares, a medical oncologist at the Huntsman Cancer Institute (HCI) at the University of Utah, to hear the latest in NET clinical trials. LACNETS Educational Event: "Genetics of NET: Do I Need Genetic Testing?" Tuesday, February 7 , 2023 Do I need genetic testing? Do my family members need to be tested? What does genetic testing entail? What genetic mutations are possible and what does it mean for my family if I carry a mutation? Join Genetic Counselor Samantha Greenberg of University of Texas, Southwestern for a discussion about genetic testing for NETs. LACNETS Educational Event : "Novel Translational Research for Metastatic NET Patients at the NCI" Friday, January 27, 2023 Join LACNETS for this special educational event. What if you could both undergo surgery for your metastatic disease and also donate your liver tumor to find a cure for NET? Learn how you can contribute to NET research. The NET team at the National Cancer Institute (NCI) will give us a behind-the-scenes look at their innovative NET research. Be inspired by their hard work and dedication to the NET community. LACNETS Educational Event: Focus on Pheochromocytoma/Paraganglioma Wednesday, January 11, 2023 Join LACNETS for a unique webinar with a live presentation of three pheochromocytoma and paraganglioma (PPGL) cases and an engaging panel discussion with experts Dr. Jaydira Del Rivero, Dr. Erik Mittra, and Dr. Karel Pacak. Click here for our video library for more educational videos